PMV Pharmaceuticals
PMVP
54 hedge funds and large institutions have $36.8M invested in PMV Pharmaceuticals in 2025 Q2 according to their latest regulatory filings, with 7 funds opening new positions, 13 increasing their positions, 20 reducing their positions, and 8 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
2% less funds holding
Funds holding: 55 → 54 (-1)
5.11% less ownership
Funds ownership: 71.87% → 66.76% (-5.1%)
10% less capital invested
Capital invested by funds: $40.7M → $36.8M (-$3.92M)
13% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 8
35% less repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 20
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $8K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCM
BML Capital Management
Zionsville,
Indiana
|
+$1.23M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$238K |
| 3 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
+$212K |
| 4 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$145K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$43.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$3.6M |
| 2 |
D.E. Shaw & Co
New York
|
-$296K |
| 3 |
Connor, Clark & Lunn Investment Management (CC&L)
Vancouver,
British Columbia, Canada
|
-$292K |
| 4 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$142K |
| 5 |
Millennium Management
New York
|
-$129K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
51
BNP Paribas Financial Markets
Paris,
France
| $578 | +$1 | +1 | +0.2% |
|
52
Raymond James Financial
St Petersburg,
Florida
| $212 | +$196 | +200 | New |
|
|
PHS
53
PFM Health Sciences
San Francisco,
California
| – | -$3.6M | -3,301,942 | Closed |
|
|
54
Connor, Clark & Lunn Investment Management (CC&L)
Vancouver,
British Columbia, Canada
| – | -$292K | -267,636 | Closed |
|
|
55
Jacobs Levy Equity Management
Florham Park,
New Jersey
| – | -$142K | -129,914 | Closed |
|
56
T. Rowe Price Associates
Baltimore,
Maryland
| – | -$37K | -33,600 | Closed |
|
57
Ameriprise
Minneapolis,
Minnesota
| – | -$19.6K | -18,007 | Closed |
|
58
Wells Fargo
San Francisco,
California
| – | -$10.9K | -10,000 | Closed |
|
59
Ohio Public Employees Retirement System (OPERS)
Columbus,
Ohio
| – | -$2.28K | -2,092 | Closed |
|
60
Fidelity Investments
Boston,
Massachusetts
| – | -$343 | -315 | Closed |
|
61
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | +$65 | +66 | +17% |
|
62
Simplex Trading
Chicago,
Illinois
| – | +$70 | +71 | New |
|
PMVP Hedge Fund Activity: Q2 2025 in Review
54 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in PMV Pharmaceuticals (PMVP) for Q2 2025, worth a combined $36.8M — down 9.6% from $40.7M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of PMVP and 7 opened new positions — a net loss of 1 holder — while 20 trimmed existing stakes and 13 added.
The largest buyer was BML Capital Management, adding an estimated $1.23M. The largest seller was PFM Health Sciences, exiting entirely with an estimated $3.6M sold.
- 54 institutional investors held PMV Pharmaceuticals (PMVP) as of Q2 2025, down from 55 in Q1 2025.
- Funds reported $36.8M of PMV Pharmaceuticals stock for Q2 2025, down 9.6% quarter-over-quarter.
- 7 funds opened new PMV Pharmaceuticals positions in Q2 2025 and 8 closed out, a net change of -1 holder.
- The largest PMV Pharmaceuticals buyer in Q2 2025 was BML Capital Management, an estimated $1.23M added.
- The largest PMV Pharmaceuticals seller in Q2 2025 was PFM Health Sciences, an estimated $3.6M sold.
Based on aggregated 13F filings for Q2 2025.